Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00685256 · ClinicalTrials.gov registry record · Phase 3
Standard Genetic Counseling With or Without a Decision Guide in Improving Communication Between Mothers Undergoing BRCA1/2 Testing and Their Minor-Age Children
A Phase 3 study of Breast Cancer and Hereditary Breast/Ovarian Cancer (brca1, brca2), sponsored by Georgetown University.
- Completed
- Registry status
- Phase 3
- Development phase
- 245
- Enrollment target
- 2
- Study locations
NCT00685256: Completed Phase 3 study of Breast Cancer and Hereditary Breast/Ovarian Cancer (brca1, brca2), sponsored by Georgetown University.
NCT00685256 is a Phase 3 study of Breast Cancer and Hereditary Breast/Ovarian Cancer (brca1, brca2) that has completed, run by Georgetown University. The registered enrollment target is 245 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (91% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00685256, a Phase 3 study of Breast Cancer and Hereditary Breast/Ovarian Cancer (brca1, brca2), has completed, sponsored by Georgetown University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 245 participants
- Enrollment target
- 2
- Study locations
Study Summary
RATIONALE: A study that evaluates the support of a decision guide used together with genetic counseling may improve communication between mothers undergoing BRCA1/2 testing and their minor-age children. PURPOSE: This randomized phase III trial is studying standard genetic counseling given together with a decision guide to see how well it works compared with genetic counseling alone in improving communication between mothers undergoing BRCA1/2 testing and their minor-age children.
Conditions Studied
Interventions
- OTHER survey administration
- OTHER educational intervention
- OTHER counseling intervention
- BEHAVIORAL psychosocial assessment and care
- BEHAVIORAL supportive care
Study Locations (2)
District of Columbia
- Lombardi Comprehensive Cancer Center at Georgetown University Medical Center - Washington D.C.
Massachusetts
- Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 245 participants |
| Start Date | 2008-03 |
| Est. Completion | 2015-12 |
| Phase | Phase 3 |
What the finished NCT00685256 record still lists
NCT00685256 is an interventional study that assigns participants to a tested intervention. The registered 245 participants enrollment target is mid-sized for trials with a published cap, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (91% lower).
The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 5 interventions - of which survey administration is the first listed.
NCT00685256 reports a single indexed study location in District of Columbia, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00685256 about?
NCT00685256 is a clinical study titled "Standard Genetic Counseling With or Without a Decision Guide in Improving Communication Between Mothers Undergoing BRCA1/2 Testing and Their Minor-Age Children". RATIONALE: A study that evaluates the support of a decision guide used together with genetic counseling may improve communication between mothers undergoing BRCA1/2 testing and their minor-age children. PURPOSE: This randomized phase III trial is studying standard genetic counseling given together ...
What is the current status of trial NCT00685256?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 245 participants. The study started on 2008-03. Estimated completion is 2015-12.
What conditions does trial NCT00685256 study?
This clinical trial studies the following conditions: Breast Cancer, Hereditary Breast/Ovarian Cancer (brca1, brca2).
What interventions are being tested in trial NCT00685256?
The interventions under investigation include: survey administration (OTHER), educational intervention (OTHER), counseling intervention (OTHER), psychosocial assessment and care (BEHAVIORAL), supportive care (BEHAVIORAL).
Who is sponsoring clinical trial NCT00685256?
This trial is sponsored by Georgetown University, which has 227 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00685256 being conducted?
This trial has 2 study locations across District of Columbia, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00685256's enrollment target sits among peer trials
245 333rd of 1224 higher than 892 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
RECRUITING · Phase 3
-
Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy
RECRUITING · Phase 3
-
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
RECRUITING · Phase 3
-
A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer
RECRUITING · Phase 3
-
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03645928 · 245 participants · Phase 2
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
- NCT04718168 · 245 participants · NA
GORE® ENFORM Biomaterial Product Study
- NCT05145127 · 245 participants · Phase 3
Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
- NCT05446259 · 245 participants
Degenerative Cervical Myelopathy Repository
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia